Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells.

Abstract

Aberration in cell cycle has been shown to be a common occurrence in lung cancer, and cell cycle inhibitor represents an effective therapeutic strategy. In this study, we test the effects of a natural macrocyclic depsipeptide largazole on lung cancer cells and report that this compound potently inhibits the proliferation and clonogenic activity of lung cancer cells but not normal bronchial epithelial cells. Largazole arrests cell cycle at G1 phase with up-regulation of the expression of cyclin-dependent kinase inhibitor p21. Interestingly, largazole enhances the E2F1-HDAC1 binding affinity and induces a proteasomal degradation of E2F1, leading to suppression of E2F1 function in lung cancer but not normal bronchial epithelial cells. Because E2F1 is overexpressed in lung cancer tumor samples, these data indicate that largazole is an E2F1-targeting cell cycle inhibitor, which bears therapeutic potentials for this malignant neoplasm.

• Authors: Li-Chuan Wu, Zhe-Sheng Wen, Ya-Tao Qiu, Xiao-Qin Chen, Hao-Bin Chen, Ming-Ming Wei, Zi Liu, Sheng Jiang, Guang-Biao Zhou
• Journal: ACS medicinal chemistry letters (ACS Med Chem Lett) Vol. 4 Issue 10 Pg. 921-6 (Oct 10 2013) ISSN: 1948-5875 [Print] United States
• PMID: 24900585 (Publication Type: Journal Article)